Winter 2025
Psychedelic Psychopharmacology

This reading and study group will maintain the same membership for the 12-week period. The group will have a syllabus with readings that participants will be expected to read prior to each discussion group meeting. The format for each session will include a short review of each paper by the group leader, followed by a discussion of the content and group members’ perspectives of the topic. This is an active group and weekly participation is required. The group is ideal for clinicians, graduate students, researchers, or the public, so long as they have training or interest in the biological responses that may influence the efficacy and safety of psychedelic therapy. Readings will include publications in the academic literature. The articles will provide an overview of psychedelic effects investigated by a variety of scientific methods (pharmacodynamics, pharmacokinetics, pharmacogenomics, neuroscience) for several types of psychedelics (e.g., psilocybin, ayahuasca, MDMA, ketamine). Teachings are appropriate for healthcare professionals as well as the general public. Healthcare professionals will be able to incorporate the tools and practices offered in this program in ways beneficial to clients or patients.

A limited number of Diversity Fund scholarships are available, please complete this application, in addition to the course application.

• Describe pharmacokinetic properties of psilocybin to predict potential drug interactions and adverse effects.
• Describe pharmacokinetic properties of ayahuasca to predict potential drug interactions and adverse effects.
• Describe pharmacokinetic properties of MDMA to predict potential drug interactions and adverse effects.
• Describe pharmacokinetic properties of ketamine to predict potential drug interactions and adverse effects.
• Explain how the pharmacodynamics of psilocybin affects clinical and serological biomarkers.
• Explain how the pharmacodynamics of ayahuasca affects clinical and serological biomarkers.
• Explain how the pharmacodynamics of MDMA affects clinical and serological biomarkers.
• Explain how the pharmacodynamics of ketamine affects clinical and serological biomarkers.
• Discuss the effects of psilocybin on neural network function.
• Discuss the effects of ayahuasca on neural network function.
• Discuss the effects of MDMA on neural network function.
• Discuss the effects of ketamine on neural network function.

• Fluence International, Inc. is approved by the American Psychological Association to sponsor continuing education for psychologists. Fluence maintains responsibility for this program and its content.
• Fluence International, Inc. is recognized by the New York State Education Department’s State Board for Mental Health Practitioners as an approved provider of continuing education for licensed mental health counselors. #MHC-0232.
• Fluence International, Inc. is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0674.
• Fluence International, Inc. is recognized by the New York State Education Department’s State Board for Psychology as an approved provider of continuing education for licensed psychologists #PSY-0167.
• The Department’s approval of a provider of continuing education does not constitute the Department’s endorsement of the content, positions or practices that may be addressed in any specific continuing education course offered by the approved provider.
• For questions about receiving your CE Certificate or Certificate of Attendance, contact Drew Ribadeneyra, drew@fluencetraining.com.